CoChat
Sign Up
Cited by 0Neuroinflammation and Neurodegeneration MechanismsAlzheimer's disease research and treatmentsMultiple Sclerosis Research Studies

Targeting Microglial Transcriptional Reprogramming as a Therapy Strategy for Alzheimer's Disease

Open access
Kim, Byungwook, Wang, Selena S., Kim, Justin R., Kim, Jungsu·2026·BioEssays
DOI 10.1002/bies.70186PMC PMC13623112
Open this paper in CoChat — free accountOpen PDF

Abstract

Recent human genetic studies revealed that Alzheimer's disease risk loci are enriched in genes expressed in myeloid cells, including microglia, the brain's resident immune cells. Notably, several risk‐associated genes, such as SPI1 and MEF2C , encode transcription factors (TFs) that control critical microglial functions, including phagocytosis, inflammatory responses, and neurotrophic support. The objective of this article is to review the recent progress in understanding these TFs and evaluate them as therapeutic targets rather than as markers of microglial state. We examine the genetic evidence implicating PU.1, MEF2C, IRF8, and BHLHE40/41, the in vivo evidence from animal models, the transcriptional network these factors regulate, and the barriers to clinical translation. Because these TFs orchestrate broad gene expression networks by regulating multiple disease‐relevant downstream partners, targeting their expression level or activity could achieve greater therapeutic efficacy than targeting single genes, provided that the dose and disease stage of modulation are carefully considered.

AI snapshot

Written from the paper’s full text.

TL;DR

This review argues that microglial transcription factors—especially PU.1, MEF2C, IRF8, and BHLHE40/41—are promising Alzheimer’s disease therapeutic targets because they coordinate broad disease-relevant gene networks rather than single pathways. It synthesizes human genetic, epigenomic, and mouse-model evidence while emphasizing unresolved dosing, disease-stage, delivery, and safety barriers before clinical translation.

Key findings

  • Alzheimer’s disease risk loci are enriched in myeloid/microglial genes. Protective associations are reported for *SPI1*/PU.1 SNPs rs1057233, rs3740688, and rs78245530, and for *MEF2C* rs190982; *MEF2C* rs9293506 is associated with increased risk of cognitive aging.
  • PU.1 modulation shows context-dependent effects in mice: PU.1 knockdown in 4-month APPPS1-21 mice increased Aβ levels, amyloid burden, microgliosis, and astrogliosis and decreased Aβ phagocytosis, whereas PU.1 overexpression in 4-month 5xFAD mice reduced Aβ levels, amyloid burden, microgliosis, astrogliosis, dystrophic neurites, and increased Aβ phagocytosis. A PU.1 inhibitor (A11) given daily for 6 weeks reduced Aβ plaque burden in 12-month 5xFAD mice and reduced phosphorylated tau with improved learning/memory in 12-month PS19 mice.
  • MEF2C knockdown in APP/PS1 mice at 6 and 10 months increased amyloid burden and apoptosis, reduced PSD95 and synaptophysin, and impaired learning/memory; Mef2a/c overexpression in 6-month PS19 mice improved cognition and reduced hyperexcitability. IRF8 deletion in 12-month female 5xFAD mice reduced plaque size but increased plaque number, while in 6-month male mice it reduced Methoxy-X04-positive microglia.
  • PU.1, IRF8, and BHLHE40/41 regulate immune/phagocytic, inflammatory, lipid-clearance, and lysosomal programs; MEF2C acts as a counterbalance suppressing excessive pro-inflammatory responses. BHLHE40/41 repress LXR:RXR- and MiT/TFE-family-driven lipid and lysosomal transcriptional responses, including TFEB.

Methods

  • Narrative review integrating human Alzheimer’s disease genetics, epigenomic/regulatory network evidence, and functional studies in cell and mouse models.
  • Summarizes microglial transcription factor risk variants in Table 1, regulatory targets/functions in Table 2, and mouse-model studies in Table 3.
  • Main analysis is a synthesis of cited literature; no new primary experimental data are reported.

Limitations

  • The paper states that microglial transcription factors have not yet progressed to human clinical trials and that barriers include peripheral immune disruption from systemic modulation, blood–brain barrier drug delivery, off-target effects, nonlinear dose–response relationships, and the need to define optimal dosage and disease stage.
  • The paper states that PU.1 studies appear conflicting and require further investigation into treatment duration, drug formulation, and disease stage; IRF8 phenotypes are complex and need age-matched, same-sex mice for plaque and in vivo phagocytosis assays.
  • Evident from the text: as a review, conclusions rely on preclinical mouse and in vitro evidence, and direct links between BHLHE family proteins and Aβ or tau pathology are not yet well established.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1002/bies.70186

Cites

87 of 87 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Claims the paper makes

163 of 195 cited sources checked · 43 supported · 5 flagged · accuracy not yet measured

  • Premisecitation

    Irf8 deletion in microglia did not alter overall Aβ accumulation in both 4- or 12-month-old 5xFAD female mice.

    “Notably, Irf8 deletion in the microglia did not alter overall Aβ accumulation in both 4‐ or 12‐month‐old 5xFAD female mice.”
    Quote in the paperNot a substantial claim1 of 1 sources checked
    • cites [35] K. Saeki, R. Pan, E. Lee, D. Kurotaki, et al., “ IRF8 defines the Epigenetic Landscape in Postnatal Microglia, Thereby Directing Their Transcriptome Programs,” Nature Immunology 25 (2024): 1928– 1942, 10.1038/s41590-024-01962-2. 39313544 source

      In “Irf8 deletion ameliorates AD pathology in the 5xFAD mouse model” (page not available), the paper reports that amyloid load was smaller in year-old 5xFAD/IRF8KO brains than in controls. It says the number of ThioS-positive aggregates was similar, but that is not the same as unchanged overall Aβ accumulation. The cited passage does not report the claimed result for four-month-old female mice. (LLM, conf=0.88)

      Checked by a reasoning model — may be wrong.

      Experimental — accuracy not yet measured
  • Interpretationcitation

    Microglial activation and functional changes in cortical and hippocampal regions during Alzheimer's disease pathology may be ameliorated through transcriptional remodeling within microglia.

    “microglial activation and functional changes, prominently observed in cortical and hippocampal regions during Alzheimer's disease pathology, may be ameliorated through transcriptional remodeling within microglia”
    Quote in the paperSubstantial claim5 of 6 sources checked
    • cites [35] K. Saeki, R. Pan, E. Lee, D. Kurotaki, et al., “ IRF8 defines the Epigenetic Landscape in Postnatal Microglia, Thereby Directing Their Transcriptome Programs,” Nature Immunology 25 (2024): 1928– 1942, 10.1038/s41590-024-01962-2. 39313544 source

      The Introduction and the section ‘Irf8 deletion ameliorates AD pathology in the 5xFAD mouse model’ report altered microglial gene expression after Irf8 deletion alongside reduced amyloid burden in an Alzheimer’s mouse model; the figure description locates the plaque and neuronal analyses in the cortex. The paper does not establish that transcriptional remodeling ameliorates microglial activation or functional changes in both cortical and hippocampal regions. No page numbers are available in our copy. (LLM, conf=0.85)

      Experimental — accuracy not yet measured
    • cites [40] B. Kim, L. C. Dabin, M. D. Tate, H. Karahan, et al., “ Effects of SPI1‐mediated Transcriptome Remodeling on Alzheimer's Disease‐related Phenotypes in Mouse Models of Aβ Amyloidosis,” Nature Communications 15 (2024): 3996, 10.1038/s41467-024-48484-x. PMC11088624 38734693 source

      The Results sections on gliosis and NanoString analysis report that Spi1 overexpression reduced cortical microgliosis in an Aβ amyloidosis mouse model and altered expression of microglial genes. The paper reports improvement in a hippocampal measure of neuronal toxicity, but the cited passages do not show amelioration of hippocampal microglial activation or function; the claim extends the microglial finding to that region. (LLM, conf=0.86)

      Experimental — accuracy not yet measured
    • cites [41] S.‐F. Lau, C. Chen, W.‐Y. Fu, J. Y. Qu, et al., “ IL‐33‐PU.1 Transcriptome Reprogramming Drives Functional State Transition and Clearance Activity of Microglia in Alzheimer's Disease,” Cell Reports 31 (2020): 107530, 10.1016/j.celrep.2020.107530. 32320664 source
    • cites [42] W. T. Ralvenius, A. E. Mungenast, H. Woolf, M. M. Huston, et al., “ A Novel Molecular Class That Recruits HDAC/MECP2 Complexes to PU.1 Motifs Reduces Neuroinflammation,” Journal of Experimental Medicine 220 (2023): 20222105, 10.1084/jem.20222105. PMC10465325 37642942 source

      The Results ('Functional and transcriptomic effect of A11 in iMGLs' and 'Investigating the mechanism of action of A11'; page unavailable) show that A11 changes inflammatory gene expression in microglia-like cells and isolated mouse microglia. Results in AD-related mouse models also show reduced hippocampal inflammatory markers and pathology. The paper does not establish that these effects occur prominently in both cortical and hippocampal regions during human Alzheimer’s disease; its cortical measurement concerns drug distribution, and the Discussion calls the models imperfect. (LLM, conf=0.85)

      Experimental — accuracy not yet measured
    • cites [48] J. Ren, S. Zhang, X. Wang, Y. Deng, et al., “ MEF2C ameliorates Learning, Memory, and Molecular Pathological Changes in Alzheimer's Disease in Vivo and in vitro,” Acta Biochimica et Biophysica Sinica (Shanghai) 54 (2022) 77– 90, 10.3724/abbs.2021012. PMC9909301 35130621 source

      The Introduction (page unavailable) says that activating the Nrf2-ARE pathway can reduce inflammatory cytokine release from microglia in an Alzheimer’s mouse model. It does not establish transcriptional remodeling within microglia as the mechanism or locate the claimed microglial changes in both cortical and hippocampal regions. The paper’s Discussion (page unavailable) instead describes its own MEF2C findings in the cortex and neuronal cells. (LLM, conf=0.78)

      Experimental — accuracy not yet measured
    • cites [49] S. J. Barker, R. M. Raju, N. E. P. Milman, J. Wang, et al., “ MEF2 is a Key Regulator of Cognitive Potential and Confers Resilience to Neurodegeneration,” Science Translational Medicine 13 (2021): abd7695, 10.1126/scitranslmed.abd7695. PMC9258338 34731014 source

      In Results, Subhead 5 (page unavailable), the paper reports differences in microglial gene expression between cognitively resilient and non-resilient individuals. But it finds no enrichment of MEF2 targets in microglial subclusters and identifies the resilience-associated MEF2 transcriptional activity as specific to excitatory neurons, not microglia. It does not report amelioration of microglial activation in cortical or hippocampal regions. (LLM, conf=0.84)

      Checked by a reasoning model — may be wrong.

      Experimental — accuracy not yet measured
    • Rests on an assumption: Findings from mouse models of Alzheimer's disease are predictive of human Alzheimer's disease.
  • Premisecitation

    The lack of readily druggable pockets for most transcription factors is a challenge for targeting them therapeutically.

    “These include the inherent complexity of their protein‒protein interactions [15] and the lack of readily druggable pockets for most transcription factors [16].”
    Quote in the paperNot a substantial claim1 of 1 sources checked
    • cites [16] M. Ali and Y. Ivarsson, “ High‐throughput Discovery of Functional Disordered Regions,” Molecular systems biology 14 (2018): 8377, 10.15252/msb.20188377. PMC5974509 29789308 source

      The discussion of transactivation domains in the paper’s Abstract describes disordered regions and their binding to coactivators, but does not address whether most transcription factors lack druggable pockets or whether that limits therapeutic targeting. Searches for druggable pockets and therapeutic targeting found no passage addressing that claim (page not available in our copy). (LLM, conf=0.72)

      Experimental — accuracy not yet measured
  • Premisecitation

    By orchestrating gene expression, transcription factors influence whether microglia play protective or detrimental roles in maintaining brain homeostasis and responding to disease.

    “By orchestrating gene expression, transcription factors influence whether microglia play protective or detrimental roles in maintaining brain homeostasis and responding to disease [8, 13].”
    Quote in the paperSubstantial claim2 of 2 sources checked
    • cites [8] O. Butovsky and H. L. Weiner, “ Microglial Signatures and Their Role in Health and Disease,” Nature Reviews Neuroscience 19 (2018): 622– 635, 10.1038/s41583-018-0057-5. PMC7255106 30206328 source
    • cites [13] H. Yeh and T. Ikezu, “ Transcriptional and Epigenetic Regulation of Microglia in Health and Disease,” Trends in Molecular Medicine 25 (2019): 96– 111, 10.1016/j.molmed.2018.11.004. PMC6377292 30578089 source
  • Premisecitation

    Alzheimer's disease risk loci are enriched in genes expressed in myeloid cells, including microglia.

    “Recent human genetic studies revealed that Alzheimer's disease risk loci are enriched in genes expressed in myeloid cells, including microglia, the brain's resident immune cells.”
    • Also stated in: § Introduction · plain
      “Recent human genetic studies of Alzheimer's disease have highlighted the role of the immune system and neuroinflammation in the onset of disease by identifying genetic variants associated with Alzheimer's disease, particularly those expressed in microglia [5, 6, 7].”
    Quote in the paperSubstantial claim3 of 3 sources checked
    • cites [5] R. Kosoy, J. F. Fullard, B. Zeng, J. Bendl, et al., “ Genetics of the human Microglia Regulome Refines Alzheimer's Disease Risk Loci,” Nature Genetics 54 (2022): 1145– 1154, 10.1038/s41588-022-01149-1. PMC9388367 35931864 source

      The Results section (‘Chromatin accessibility and gene expression in microglia’; page unavailable) reports enrichment of Alzheimer’s disease risk variants in microglial open chromatin regions. That supports a role for microglia, which the paper identifies as brain myeloid cells, but it does not establish the claimed enrichment in genes expressed across myeloid cells. (LLM, conf=0.84)

      Experimental — accuracy not yet measured
    • cites [6] K. D. P. Lopes, G. J. L. Snijders, J. Humphrey, A. Allan, et al., “ Genetic Analysis of the human Microglial Transcriptome Across Brain Regions, Aging and Disease Pathologies,” Nature Genetics 54 (2022): 4– 17, 10.1038/s41588-021-00976-y. PMC9245609 34992268 source

      The Introduction identifies microglia as myeloid immune cells and says genetic evidence suggests some neurological disease risk acts through myeloid cells. The Results report Alzheimer’s disease risk loci that colocalize with microglial gene-expression signals, but do not establish that Alzheimer’s risk loci are enriched in genes expressed in myeloid cells. (LLM, conf=0.84)

      Experimental — accuracy not yet measured
    • cites [7] X. Yang, J. Wen, H. Yang, I. R. Jones, et al., “ Functional Characterization of Alzheimer's Disease Genetic Variants in Microglia,” Nature Genetics 55 (2023): 1735– 1744, 10.1038/s41588-023-01506-8. PMC10939305 37735198 source

      The Introduction reports that microglial regulatory elements have high enrichment for AD-associated variants, and the Results section on AD fine-mapping reports enrichment of AD SNP heritability in microglial regulatory elements. This supports the microglia connection, but these passages do not establish enrichment in genes expressed across myeloid cells generally. (LLM, conf=0.84)

      Experimental — accuracy not yet measured
  • May combine two claims. 26
  • Classified as probably not a substantial claim. 10
  • The quote only partly states this claim. 9

  • May combine two claims.

    Premisecitation

    The SNP rs78245530 is significantly associated with Alzheimer's disease in Chinese populations and is suggested to reduce the risk of developing Alzheimer's disease in that population.

    “Furthermore, the SNPs rs3740688 and rs78245530 are significantly associated with Alzheimer's disease in European [23] and Chinese [24] populations, respectively. Interestingly, these variants are also suggested to reduce the risk of developing Alzheimer's disease in these specific populations [23, 24].”
    Quote in the paperNot a substantial claim1 of 1 sources checked
    • cites [24] H. Cao, X. Zhou, Y. Chen, F. C. F. Ip, et al., “ Association of SPI1 Haplotypes With Altered SPI1 Gene Expression and Alzheimer's Disease Risk,” Journal of Alzheimer's Disease 86 (2022): 1861– 1873, 10.3233/JAD-215311. PMC9108557 35253752 source

      In Results, Table 1, rs78245530 is not significantly associated with Alzheimer’s disease in the Chinese cohort (p = 0.361). The Introduction states that, among the three SNPs tested, only rs3740688 had a significant protective effect in that cohort. The paper does report a protective haplotype tagged in part by rs78245530, but not a significant protective association for that SNP itself. (LLM, conf=0.90)

      Checked by a reasoning model — may be wrong.

      Experimental — accuracy not yet measured

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Premisecitation

    BHLHE40 suppresses proinflammatory cytokine production, helping to control immune responses.

    “BHLHE40, in particular, is known to suppress proinflammatory cytokine production, helping to control immune responses [52].”
    Quote in the paperNot a substantial claim1 of 1 sources checked
    • cites [52] S. V. Hendrix, Y. Mreyoud, M. E. McNehlan, A. Smirnov, et al., “ BHLHE40 Regulates Myeloid Cell Polarization Through IL‐10–Dependent and –Independent Mechanisms,” The Journal of Immunology 212 (2024): 1766– 1781, 10.4049/jimmunol.2200819. PMC11105981 38683120 source

      The Introduction and Discussion say BHLHE40 promotes pro-inflammatory responses in the myeloid cells studied, rather than suppressing them. The results section reports that loss of BHLHE40 decreased production of several pro-inflammatory cytokines. (LLM, conf=0.91)

      Checked by a reasoning model — may be wrong.

      Experimental — accuracy not yet measured

  • May combine two claims.

    Premisecitation

    In 12-month-old female mice, microglial Irf8 deletion reduced plaque size while increasing the number of plaques.

    “However, in 12‐month‐old female mice, microglial Irf8 deletion reduced plaque size while increasing the number of plaques [35].”
    Quote in the paperNot a substantial claim1 of 1 sources checked
    • cites [35] K. Saeki, R. Pan, E. Lee, D. Kurotaki, et al., “ IRF8 defines the Epigenetic Landscape in Postnatal Microglia, Thereby Directing Their Transcriptome Programs,” Nature Immunology 25 (2024): 1928– 1942, 10.1038/s41590-024-01962-2. 39313544 source

      The ‘Irf8 deletion ameliorates AD pathology’ section reports smaller plaques in year-old 5xFAD/IRF8KO mice, consistent with the size claim. But it says the number of ThioS-positive aggregates was similar to that in 5xFAD/WT mice, not increased. Figure 7’s caption identifies these as measurements from year-old brains; the Methods state that female mice were used unless specified. (LLM, conf=0.90)

      Checked by a reasoning model — may be wrong.

      Experimental — accuracy not yet measured

  • Classified as probably not a substantial claim.

    Premisecitation

    Transcription factors play crucial roles in regulating gene expression.

    “Transcription factors play crucial roles in regulating gene expression, a fundamental process essential for all cellular functions [12].”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [12] S. A. Lambert, A. Jolma, L. F. Campitelli, P. K. Das, et al., “ The Human Transcription Factors,” Cell 172 (2018): 650– 665, 10.1016/j.cell.2018.01.029. PMC12908702 29425488 source

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Premisecitation

    Recent advancements in drug discovery, such as novel chemical libraries and protein engineering techniques, are paving the way for overcoming obstacles to targeting transcription factors.

    “However, recent advancements in drug discovery, such as the development of novel chemical libraries and protein engineering techniques, are paving the way for overcoming these obstacles [15, 17, 18].”
    Quote in the paperNot a substantial claim2 of 3 sources checked
    • cites [15] M. J. Henley and A. N. Koehler, “ Advances in Targeting ‘Undruggable’ transcription Factors With Small Molecules,” Nature Reviews Drug Discovery 20 (2021): 669– 688, 10.1038/s41573-021-00199-0. 34006959 source
    • cites [17] A. S. Bhagwat and C. R. Vakoc, “ Targeting Transcription Factors in Cancer,” Trends in Cancer 1 (2015): 53– 65, 10.1016/j.trecan.2015.07.001. PMC4669894 26645049 source

      The Introduction and Concluding Remarks describe emerging chemical strategies and high-throughput chemical screens as ways to target transcription factors. They do not identify novel chemical libraries or protein engineering techniques as the advances overcoming these obstacles; no page numbers are supplied in our copy. (LLM, conf=0.87)

      Experimental — accuracy not yet measured
    • cites [18] J. H. Bushweller, “ Targeting Transcription Factors in Cancer — From Undruggable to Reality,” Nature Reviews Cancer 19 (2019): 611– 624, 10.1038/s41568-019-0196-7. PMC8820243 31511663 source

      The Abstract and Future directions sections describe substantial progress and new approaches for targeting transcription factors, supporting the broad claim that drug-development advances are helping overcome earlier obstacles. The passages do not identify novel chemical libraries or protein engineering techniques as the advances responsible; searches for those terms found no supporting passage. Page numbers were not available in our copy. (LLM, conf=0.85)

      Experimental — accuracy not yet measured

  • May combine two claims.

    Premisecitation

    The SNP rs3740688 is significantly associated with Alzheimer's disease in European populations and is suggested to reduce the risk of developing Alzheimer's disease in that population.

    “Furthermore, the SNPs rs3740688 and rs78245530 are significantly associated with Alzheimer's disease in European [23] and Chinese [24] populations, respectively. Interestingly, these variants are also suggested to reduce the risk of developing Alzheimer's disease in these specific populations [23, 24].”
    Quote in the paperNot a substantial claim1 of 1 sources checked
    • cites [23] B. W. Kunkle, B. Grenier‐Boley, R. Sims, J. C. Bis, et al., “ Genetic Meta‐analysis of Diagnosed Alzheimer's Disease Identifies New Risk Loci and Implicates Abeta, tau, Immunity and Lipid Processing,” Nature Genetics 51 (2019): 414– 430, 10.1038/s41588-019-0358-2. PMC6463297 30820047 source

      The Main Text reports Alzheimer’s disease associations for other named variants, but the available passages do not identify rs3740688 or give an association or protective effect for it. Searches for rs3740688 and for a protective association in Europeans found no passage addressing that SNP; the cited claim therefore cannot be verified from our copy. (LLM, conf=0.72)

      Experimental — accuracy not yet measured

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Premisecitation

    PU.1 binds specific DNA sequences known as ETS motifs, which are located predominantly in enhancers but also in promoters of target genes.

    “PU.1, as an ETS family transcription factor, binds specific DNA sequences known as ETS motifs, which are located predominantly in the enhancers but also in the promoters of target genes [30, 31].”
    Quote in the paperNot a substantial claim2 of 2 sources checked
    • cites [30] S. J. Taylor, J. Stauber, O. Bohorquez, G. Tatsumi, et al., “ Pharmacological Restriction of Genomic Binding Sites Redirects PU.1 Pioneer Transcription Factor Activity,” Nature Genetics 56 (2024): 2213– 2227, 10.1038/s41588-024-01911-7. PMC11525197 39294495 source

      The Results section (‘Pharmacological binding site restriction repositions PU.1’; page unavailable) reports enrichment of ETS motifs at PU.1 binding sites and identifies some sites in promoter regions. It does not establish that PU.1 binding sites are predominantly in enhancers, so that part of the claim is unsupported by our copy. (LLM, conf=0.84)

      Experimental — accuracy not yet measured
    • cites [31] J. Minderjahn, A. Schmidt, A. Fuchs, R. Schill, et al., “ Mechanisms Governing the Pioneering and Redistribution Capabilities of the Non‐classical Pioneer PU.1,” Nature Communications 11 (2020): 402. PMC6972792 31964861 source

      The Results sections on PU.1 binding and ETS-family interactions show that PU.1 binds sequence-specific motifs and that PU.1-binding sites can occur in promoters. The Discussion links PU.1 to enhancer establishment, but the passages do not establish that its binding sites are predominantly in enhancers rather than promoters. Page numbers are unavailable in our copy. (LLM, conf=0.83)

      Experimental — accuracy not yet measured

  • May combine two claims.

    Premisecitation

    PU.1 functions both intrinsically and through the regulation of its target genes Irf8, Csf1, and Csf1r.

    “It functions both intrinsically and through the regulation of its target genes Irf8, colony stimulating Factor 1 (Csf1), and Csf1 receptor (Csf1r) [32], which are themselves known to be critical for microglial survival and proliferation [33, 34, 35].”
    Quote in the paperNot a substantial claim1 of 1 sources checked
    • cites [32] J. Satoh, N. Asahina, S. Kitano, and Y. Kino, “ A Comprehensive Profile of ChIP‐Seq‐Based PU.1/Spi1 Target Genes in Microglia,” Gene Regulation and Systems Biology 8 (2014): GRSBS19711, 10.4137/GRSB.S19711. PMC4262374 25574134 source

  • May combine two claims.

    Findingcitation

    In amyloidosis mouse models, PU.1 knockdown increased gliosis, whereas PU.1 overexpression decreased it.

    “In contrast to a previous in vitro study reporting that knockdown of PU.1 reduces neuroinflammation [37], our findings in amyloidosis mouse models revealed that PU.1 knockdown increased gliosis, whereas PU.1 overexpression decreased it [40].”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [40] B. Kim, L. C. Dabin, M. D. Tate, H. Karahan, et al., “ Effects of SPI1‐mediated Transcriptome Remodeling on Alzheimer's Disease‐related Phenotypes in Mouse Models of Aβ Amyloidosis,” Nature Communications 15 (2024): 3996, 10.1038/s41467-024-48484-x. PMC11088624 38734693 source

  • May combine two claims.

    Premisecitation

    Oral administration of a functional PU.1 inhibitor for six weeks reduced amyloid plaque deposition in a 1-year-old amyloid mouse model and decreased tau phosphorylation in a 1-year-old tauopathy mouse model.

    “In contrast, another recent study reported that oral administration of a functional PU.1 inhibitor for six weeks reduceed amyloid plaque deposition in a 1‐year‐old amyloid mouse model and decreases tau phosphorylation in a 1‐year‐old tauopathy mouse model [42].”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [42] W. T. Ralvenius, A. E. Mungenast, H. Woolf, M. M. Huston, et al., “ A Novel Molecular Class That Recruits HDAC/MECP2 Complexes to PU.1 Motifs Reduces Neuroinflammation,” Journal of Experimental Medicine 220 (2023): 20222105, 10.1084/jem.20222105. PMC10465325 37642942 source

      The Results section reports that six weeks of A11 treatment reduced phosphorylated tau in 1-year-old P301STau mice and hippocampal β-amyloid accumulation in 1-year-old 5XFAD mice. However, A11 was administered by daily intraperitoneal injection, not orally; the claim's administration route is unsupported. (LLM, conf=0.94)

      Experimental — accuracy not yet measured

  • May combine two claims.

    Premisecitation

    Knockdown of PU.1 in BV-2 microglia stimulated with LPS reduces the expression of proinflammatory genes and immune response mediators, whereas overexpression of PU.1 has the opposite effect under the same conditions.

    “On the one hand, the knockdown of PU.1 in BV‐2 microglia stimulated with LPS reduces the expression of proinflammatory genes and immune response mediators, whereas the overexpression of PU.1 has the opposite effect under the same conditions [22, 37].”
    Quote in the paperSubstantial claim2 of 2 sources checked
    • cites [22] K. L. Huang, E. Marcora, A. A. Pimenova, A. F. Di Narzo, et al., “ A Common Haplotype Lowers PU.1 Expression in Myeloid Cells and Delays Onset of Alzheimer's Disease,” Nature neuroscience 20 (2017): 1052– 1061. PMC5759334 28628103 source

      The functional-analysis discussion (page unavailable) reports that Spi1 knockdown in BV2 cells reduced expression of several inflammatory genes and that overexpression and knockdown produced often opposite gene-expression changes. The qPCR methods describe those BV2 experiments without LPS stimulation, so the source does not support the claim's LPS-stimulated condition. (LLM, conf=0.88)

      Experimental — accuracy not yet measured
    • cites [37] A. A. Pimenova, M. Herbinet, I. Gupta, S. I. Machlovi, et al., “ Alzheimer's‐associated PU.1 Expression Levels Regulate Microglial Inflammatory Response,” Neurobiology of Disease 148 (2021): 105217, 10.1016/j.nbd.2020.105217. PMC7808757 33301878 source

  • May combine two claims.

    Premisecitation

    IL-33 indirectly induces VCAM1 expression in microglia, enhancing microglial chemotaxis toward Aβ plaques and facilitating Aβ clearance in a mouse model of amyloidosis.

    “Moreover, a recent study reported that IL‐33 indirectly induces VCAM1 expression in microglia, enhancing microglial chemotaxis toward Aβ plaques and facilitating Aβ clearance in a mouse model of amyloidosis [57].”
    Quote in the paperNot a substantial claim1 of 1 sources checked
    • cites [57] S.‐F. Lau, W. Wu, H. Y. Wong, L. Ouyang, et al., “ The VCAM1–ApoE Pathway Directs Microglial Chemotaxis and Alleviates Alzheimer's Disease Pathology,” Nature Aging 3 (2023): 1219– 1236, 10.1038/s43587-023-00491-1. PMC10570140 37735240 source

  • May combine two claims.

    Premisecitation

    AAV-induced overexpression of neuronal Mef2a/c improved cognitive function in the fear conditioning test and reduced hyperexcitability in a tauopathy mouse model.

    “Conversely, AAV‐induced overexpression of neuronal Mef2a/c improved cognitive function in the fear conditioning test and reduced hyperexcitability in a tauopathy mouse model [49].”
    Quote in the paperNot a substantial claim1 of 1 sources checked
    • cites [49] S. J. Barker, R. M. Raju, N. E. P. Milman, J. Wang, et al., “ MEF2 is a Key Regulator of Cognitive Potential and Confers Resilience to Neurodegeneration,” Science Translational Medicine 13 (2021): abd7695, 10.1126/scitranslmed.abd7695. PMC9258338 34731014 source

      Results, subhead 6, reports that AAV-mediated Mef2a/c overexpression accelerated fear-memory extinction in PS19 tauopathy mice, although initial memory acquisition did not differ. The reduced neuronal hyperexcitability was measured in PS19 mice overexpressing Mef2a/c using a lentiviral construct, not the AAV construct, so the claim attributes that result to the wrong delivery method. (LLM, conf=0.88)

      Experimental — accuracy not yet measured

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Premisecitation

    The transcription factor hematopoiesis associated factor 1 complex (HAF1) forms dimeric or trimeric configurations with PU.1, IRF1, and IRF8.

    “The transcription factor hematopoiesis associated factor 1 complex (HAF1) is known to form dimeric or trimeric configurations with the transcription factors, PU.1, IRF1, and IRF8 [61, 62].”
    Quote in the paperNot a substantial claim1 of 2 sources checked
    • cites [61] E. A. Eklund, A. Jalava, and R. Kakar, “ PU.1, Interferon Regulatory Factor 1, and Interferon Consensus Sequence‐binding Protein Cooperate to Increase gp91phox Expression*,” Journal of Biological Chemistry 273 (1998): 13957– 13965, 10.1074/jbc.273.22.13957. 9593745 source
    • cites [62] L. Wang, Y. Zhu, N. Zhang, Y. Xian, et al., “ The Multiple Roles of Interferon Regulatory Factor family in Health and Disease,” Signal Transduction and Targeted Therapy 9 (2024): 282, 10.1038/s41392-024-01980-4. PMC11486635 39384770 source

      The section on myeloid differentiation says IRF8 forms complexes with PU.1 and IRF1, but it does not identify those complexes as HAF1 or describe dimeric and trimeric HAF1 configurations. Searches for HAF1, its expanded name, and the claimed configurations found no passage addressing that point in our copy; section page numbers are unavailable. (LLM, conf=0.73)

      Experimental — accuracy not yet measured

  • May combine two claims.

    Premisecitation

    AAV-induced Mef2c knockdown increased Aβ deposition, triggered neuronal apoptosis, reduced levels of the synaptic proteins PSD95 and SYP, and impaired learning and memory abilities in an amyloid mouse model.

    “A recent study further demonstrated that AAV‐induced Mef2c knockdown increased Aβ deposition, triggered neuronal apoptosis, reduced levels of the synaptic proteins, postsynaptic density protein 95 (PSD95) and synaptophysin (SYP), and impaired learning and memory abilities in an amyloid mouse model [48].”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [48] J. Ren, S. Zhang, X. Wang, Y. Deng, et al., “ MEF2C ameliorates Learning, Memory, and Molecular Pathological Changes in Alzheimer's Disease in Vivo and in vitro,” Acta Biochimica et Biophysica Sinica (Shanghai) 54 (2022) 77– 90, 10.3724/abbs.2021012. PMC9909301 35130621 source

  • May combine two claims.

    Premisecitation

    In a 5xFAD mouse model of Alzheimer's disease, decreased microglial MEF2C nuclear translocation contributes to chronic neuroinflammation, which exacerbates neurodegeneration.

    “In a 5xFAD mouse model of Alzheimer's disease, decreased microglial MEF2C nuclear translocation contributes to chronic neuroinflammation, which exacerbates neurodegeneration [46].”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [46] F. Xue, J. Tian, C. Yu, H. Du, et al., “ Type I Interferon Response‐related Microglial Mef2c Deregulation at the Onset of Alzheimer's Pathology in 5×FAD Mice,” Neurobiology of Disease 152 (2021): 105272, 10.1016/j.nbd.2021.105272. PMC7956132 33540048 source

      The Results section reports decreased nuclear Mef2C in microglia from 5×FAD mice, alongside signs of microglial activation. The Discussion says these changes are associated but explicitly states that the study cannot establish whether Mef2C deregulation causes pro-inflammatory activation. It does not establish the claimed chain from reduced nuclear translocation to chronic neuroinflammation and worsened neurodegeneration (page numbers unavailable). (LLM, conf=0.89)

      Experimental — accuracy not yet measured

  • May combine two claims.

    Premisecitation

    MEF2C exerts anti-inflammatory effects within the brain by suppressing the expression of proinflammatory cytokines and protecting neurons from inflammatory damage.

    “MEF2C exerts anti‐inflammatory effects within the brain by suppressing the expression of proinflammatory cytokines and protecting neurons from inflammatory damage.”
    Quote in the paperSubstantial claim2 of 2 sources checked
    • cites [43] A. Assali, A. J. Harrington, and C. W. Cowan, “ Emerging Roles for MEF2 in Brain Development and Mental Disorders,” Current Opinion in Neurobiology 59 (2019): 49– 58, 10.1016/j.conb.2019.04.008. PMC6874740 31129473 source

      The References section cites a study titled “Mef2C restrains microglial inflammatory response,” supporting a brain anti-inflammatory role for MEF2C. Neither that entry nor the review’s Conclusion specifies suppression of proinflammatory cytokines or protection of neurons from inflammatory damage; the Conclusion says MEF2’s role in microglia is only beginning to be explored. The indexed passages provide no page numbers. (LLM, conf=0.84)

      Experimental — accuracy not yet measured
    • cites [44] Z. Zhang and Y. Zhao, “ Progress on the Roles of MEF2C in Neuropsychiatric Diseases,” Molecular Brain 15 (2022): 8, 10.1186/s13041-021-00892-6. PMC8740500 34991657 source

      The Alzheimer’s disease section reports higher proinflammatory cytokine levels in MEF2C-knockout mice after immune activation, supporting an anti-inflammatory role for MEF2C in microglia. It separately describes MEF2C’s role in anti-apoptotic neuroprotection, but does not say that MEF2C protects neurons specifically from inflammatory damage. (LLM, conf=0.85)

      Experimental — accuracy not yet measured

  • The quote only partly states this claim.

    Premisecitation

    In APPPS1-21 mice at 4 months of age, postnatal microglia-specific PU.1 deletion increases Aβ levels in the cortex and hippocampus.

    “Aβ levels↑, Amyloid burden↑, microgliosis↑, astrogliosis↑, Aβ phagocytosis↓, dystrophic neurites↑”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [72] B. Kim, M. D. Tate, H. Karahan, H. R. S. Wijeratne, et al., “ Deletion of SPI1 in Microglia Exacerbates Amyloid Pathology by Impairing Microglial Response in Alzheimer's disease Models,” Neuron 114 (2026): P2741– 2758.e6, 10.1016/j.neuron.2026.03.011. PMC13051965 41928507 source

  • The quote only partly states this claim.

    Premisecitation

    In APPPS1-21 mice at 4 months of age, postnatal microglia-specific PU.1 deletion increases amyloid burden in the cortex and hippocampus.

    “Aβ levels↑, Amyloid burden↑, microgliosis↑, astrogliosis↑, Aβ phagocytosis↓, dystrophic neurites↑”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [72] B. Kim, M. D. Tate, H. Karahan, H. R. S. Wijeratne, et al., “ Deletion of SPI1 in Microglia Exacerbates Amyloid Pathology by Impairing Microglial Response in Alzheimer's disease Models,” Neuron 114 (2026): P2741– 2758.e6, 10.1016/j.neuron.2026.03.011. PMC13051965 41928507 source

  • May combine two claims.

    Premisecitation

    IRF8 is directly activated by PU.1 and contributes to the activation of SALL1, CX3CR1, and STING.

    “Moreover, IRF8 is directly activated by PU.1 and contributes to the activation of SALL1, CX3CR1, and STING (also known as TMEM173) [35, 63].”
    Quote in the paperNot a substantial claim2 of 2 sources checked
    • cites [35] K. Saeki, R. Pan, E. Lee, D. Kurotaki, et al., “ IRF8 defines the Epigenetic Landscape in Postnatal Microglia, Thereby Directing Their Transcriptome Programs,” Nature Immunology 25 (2024): 1928– 1942, 10.1038/s41590-024-01962-2. 39313544 source

      The transcription-cascade results state that IRF8 activates Sall1, and the genome-binding results report IRF8 binding near Cx3cr1; the RNA-seq results also report lower CX3CR1 on IRF8-knockout microglia. These passages support IRF8’s contribution to SALL1 and CX3CR1 expression, but the copy does not establish that PU.1 directly activates IRF8 or that IRF8 activates STING/TMEM173 (searched both terms). The indexed passages provide section labels but no page numbers. (LLM, conf=0.88)

      Experimental — accuracy not yet measured
    • cites [63] W.‐W. Luo, Z. Tong, P. Cao, F.‐B. Wang, et al., “ Transcription‐independent Regulation of STING Activation and Innate Immune Responses by IRF8 in Monocytes,” Nature Communications 13 (2022): 4822, 10.1038/s41467-022-32401-1. PMC9381507 35973990 source

      The Results section ('Irf8 mediates polymerization of Sting and its recruitment of Irf3'; page not available) supports IRF8's role in STING activation after DNA virus infection. Our copy does not say that PU.1 directly activates IRF8 or that IRF8 activates SALL1 or CX3CR1; its reference to an IRF8–PU.1 complex does not establish direct activation. (LLM, conf=0.90)

      Experimental — accuracy not yet measured

  • The quote only partly states this claim.

    Premisecitation

    In APPPS1-21 mice at 4 months of age, postnatal microglia-specific PU.1 deletion increases microgliosis in the cortex and hippocampus.

    “Aβ levels↑, Amyloid burden↑, microgliosis↑, astrogliosis↑, Aβ phagocytosis↓, dystrophic neurites↑”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [72] B. Kim, M. D. Tate, H. Karahan, H. R. S. Wijeratne, et al., “ Deletion of SPI1 in Microglia Exacerbates Amyloid Pathology by Impairing Microglial Response in Alzheimer's disease Models,” Neuron 114 (2026): P2741– 2758.e6, 10.1016/j.neuron.2026.03.011. PMC13051965 41928507 source

      The Results section, “Deletion of Spi1 in microglia increases microgliosis and astrogliosis” (Figure 4B–D; page not available), reports increased IBA1-positive microglial area and cell counts in the cortex after microglial Spi1/PU.1 deletion. The Methods and Results establish postnatal tamoxifen treatment and assessment at 4 months, but the microgliosis passage does not report a corresponding hippocampal increase; hippocampal findings elsewhere concern amyloid and neuritic pathology. (LLM, conf=0.84)

      Experimental — accuracy not yet measured

  • May combine two claims.

    Premisecitation

    IRF8 reciprocally stabilizes PU.1 expression via enhancer interactions, forming a positive feedback loop that can potentiate immune activation.

    “IRF8 reciprocally stabilizes PU.1 expression via enhancer interactions, forming a positive feedback loop that can potentiate immune activation [39].”
    Quote in the paperNot a substantial claim1 of 1 sources checked
    • cites [39] N. Zhou, K. Liu, Y. Sun, Y. Cao, et al., “ Transcriptional Mechanism of IRF8 and PU.1 Governs Microglial Activation in Neurodegenerative Condition,” Protein & cell 10 (2019): 87– 103, 10.1007/s13238-018-0599-3. PMC6340890 30484118 source

  • The quote only partly states this claim.

    Premisecitation

    In APPPS1-21 mice at 4 months of age, postnatal microglia-specific PU.1 deletion increases astrogliosis in the cortex and hippocampus.

    “Aβ levels↑, Amyloid burden↑, microgliosis↑, astrogliosis↑, Aβ phagocytosis↓, dystrophic neurites↑”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [72] B. Kim, M. D. Tate, H. Karahan, H. R. S. Wijeratne, et al., “ Deletion of SPI1 in Microglia Exacerbates Amyloid Pathology by Impairing Microglial Response in Alzheimer's disease Models,” Neuron 114 (2026): P2741– 2758.e6, 10.1016/j.neuron.2026.03.011. PMC13051965 41928507 source

      The Results section, “Deletion of Spi1 in microglia increases microgliosis and astrogliosis” (page unavailable), reports increased GFAP-stained astrogliosis in the cortex of microglia-specific Spi1-deleted APPPS1–21 mice. The Results section on Aβ levels says the mice received tamoxifen at 7 weeks and were evaluated at 4 months. Our copy does not report increased astrogliosis specifically in the hippocampus; its hippocampal findings concern other outcomes. (LLM, conf=0.88)

      Experimental — accuracy not yet measured

  • May combine two claims.

    Premisecitation

    BHLHE40/41 bind to open chromatin at promoters and enhancers of LXR:RXR and MiT/TFE family transcriptional factors, acting as transcriptional repressors and modulating cholesterol/lipid efflux genes and lysosomal genes, thereby influencing cellular clearance functions.

    “BHLHE40/41 bind to open chromatin at promoters and enhancers of LXR:RXR and MiT/TFE family transcriptional factors, acting as transcriptional repressors and modulating cholesterol/lipid efflux genes and lysosomal genes, thereby influencing cellular clearance functions (Figure 1 and Table 2) [53, 54].”
    Quote in the paperSubstantial claim2 of 2 sources checked
    • cites [53] A. Podleśny‐Drabiniok, G. Novikova, Y. Liu, J. Dunst, et al., “ BHLHE40/41 regulate Microglia and Peripheral Macrophage Responses Associated With Alzheimer's Disease and Other Disorders of Lipid‐rich Tissues,” Nature Communications 15 (2024): 2058, 10.1038/s41467-024-46315-7. PMC10917780 38448474 source

      Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

      Experimental — accuracy not yet measured
    • cites [54] K. L. Carey, G. L. C. Paulus, L. Wang, D. R. Balce, et al., “ TFEB Transcriptional Responses Reveal Negative Feedback by BHLHE40 and BHLHE41,” Cell Reports 33 (2020): 108371, 10.1016/j.celrep.2020.108371. PMC7686957 33176151 source

      Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

      Experimental — accuracy not yet measured

  • May combine two claims.

    Premisecitation

    STING interacts with cGAS and plays a significant role in Alzheimer's disease by promoting microglial dysfunction and neuroinflammation.

    “The STING interacts with cGAS and plays a significant role in Alzheimer's disease by promoting microglial dysfunction and neuroinflammation [66, 67].”
    Quote in the paperSubstantial claim2 of 2 sources checked
    • cites [66] S. He, X. Li, N. Mittra, A. Bhattacharjee, et al., “ Microglial cGAS Deletion Preserves Intercellular Communication and Alleviates Amyloid‐β‐Induced Pathogenesis of Alzheimer's Disease,” Advanced Science n/a (2025): 2410910, 10.1002/advs.202410910. PMC11948024 39908354 source

      The Introduction describes cGAS activating STING through cGAMP, and the Discussion reports that microglial cGAS deletion alleviated neuroinflammation in an Alzheimer’s mouse model. This supports a role for the cGAS–STING pathway, but the study does not establish that STING itself promotes microglial dysfunction or that STING directly interacts with cGAS. (LLM, conf=0.82)

      Experimental — accuracy not yet measured
    • cites [67] J. M. Thanos, O. C. Campbell, M. N. Cowan, K. R. Bruch, et al., “ STING Deletion Protects Against Amyloid β‐induced Alzheimer's Disease Pathogenesis,” Alzheimers Dement 21 (2025): 70305, 10.1002/alz.70305. PMC12101966 40410932 source

      The Background describes cGAS as an upstream activator of STING, and the Results report that STING deletion dampened microglial activation and innate immune signaling in 5xFAD mice. But the Discussion says the cell types through which cGAS and STING promote AD-related progression remain undetermined, so the claim that STING acts *by* promoting microglial dysfunction states a mechanism more firmly than this paper establishes. (LLM, conf=0.85)

      Experimental — accuracy not yet measured

  • May combine two claims.

    Premisecitation

    PU.1 functions as a pioneer transcriptional factor that establishes enhancer accessibility in myeloid lineage cells and directly induces expression of other transcriptional factors, such as IRF8 and MEF2C.

    “Especially, PU.1 functions as a pioneer transcriptional factor that establishes enhancer accessibility in myeloid lineage cells and directly induces expression of other transcriptional factors (e.g., IRF8, MEF2C) [29, 64, 69, 70].”
    Quote in the paperSubstantial claim2 of 4 sources checked
    • cites [29] K. Kierdorf, D. Erny, T. Goldmann, V. Sander, et al., “ Microglia Emerge From Erythromyeloid Precursors via Pu.1‐ and Irf8‐dependent Pathways,” Nature neuroscience 16 (2013): 273– 280, 10.1038/nn.3318. 23334579 source
    • cites [64] S. Stehling‐Sun, J. Dade, S. L. Nutt, R. P. DeKoter, et al., “ Regulation of Lymphoid versus Myeloid Fate 'choice' by the Transcription Factor Mef2c,” Nature Immunology 10 (2009): 289– 296, 10.1038/ni.1694. 19169261 source
    • cites [69] H. Wang, S. Jain, P. Li, J. X. Lin, et al., “ Transcription Factors IRF8 and PU.1 Are Required for Follicular B Cell Development and BCL6‐driven Germinal Center Responses,” Proceedings of the National Academy of Sciences of the United States of America 116 (2019): 9511– 9520, 10.1073/pnas.1901258116. PMC6511064 31000603 source

      In “Disrupted Germinal Center Responses in DKO Mice” (page unavailable), the paper identifies Mef2c as a direct target of IRF8 and PU.1 in follicular B cells. It does not establish that PU.1 acts as a pioneer factor to open enhancers in myeloid cells or that it directly induces IRF8 expression. (LLM, conf=0.84)

      Experimental — accuracy not yet measured
    • cites [70] E. Humblin, M. Thibaudin, F. Chalmin, V. Derangère, et al., “ IRF8‐dependent Molecular Complexes Control the Th9 Transcriptional Program,” Nature Communications 8 (2017): 2085, 10.1038/s41467-017-01070-w. PMC5727025 29233972 source

      The Introduction and Discussion identify PU.1 as a transcription factor and report that it partners with IRF8 in myeloid cells. They do not say that PU.1 acts as a pioneer factor, establishes enhancer accessibility, or directly induces IRF8 or MEF2C expression. The paper instead focuses on PU.1-containing complexes that regulate Th9 cytokine transcription; page numbers were not available in our copy. (LLM, conf=0.84)

      Experimental — accuracy not yet measured

  • May combine two claims.

    Premisecitation

    The PU.1-IRF8 complex functions as an immune activator, and both transcription factors are essential for microglial activation.

    “In addition, PU.1‐IRF8 complex functions as an immune activator, and both transcription factors are essential for microglial activation [39].”
    Quote in the paperNot a substantial claim1 of 1 sources checked
    • cites [39] N. Zhou, K. Liu, Y. Sun, Y. Cao, et al., “ Transcriptional Mechanism of IRF8 and PU.1 Governs Microglial Activation in Neurodegenerative Condition,” Protein & cell 10 (2019): 87– 103, 10.1007/s13238-018-0599-3. PMC6340890 30484118 source

  • May combine two claims.

    Premisecitation

    Pharmacological inhibition of STING activation reduces microglia-mediated inflammatory response and ameliorates a wide range of Alzheimer's disease-related symptoms in AppNL-G-F/hTau double-knock-in mice.

    “For example, pharmacological inhibition of STING activation reduces microglia‐mediated inflammatory response and ameliorates a wide range of AD‐related symptoms in AppNL−G−F/hTau double‐knock‐in mice [68].”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [68] S. Chung, J.‐H. Jeong, J.‐C. Park, J. W. Han, et al., “ Blockade of STING Activation Alleviates Microglial Dysfunction and a Broad Spectrum of Alzheimer's Disease Pathologies,” Experimental & Molecular Medicine 56 (2024): 1936– 1951, 10.1038/s12276-024-01295-y. PMC11447230 39218977 source

  • The quote only partly states this claim.

    Premisecitation

    In APPPS1-21 mice at 4 months of age, postnatal microglia-specific PU.1 deletion decreases Aβ phagocytosis in the cortex and hippocampus.

    “Aβ levels↑, Amyloid burden↑, microgliosis↑, astrogliosis↑, Aβ phagocytosis↓, dystrophic neurites↑”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [72] B. Kim, M. D. Tate, H. Karahan, H. R. S. Wijeratne, et al., “ Deletion of SPI1 in Microglia Exacerbates Amyloid Pathology by Impairing Microglial Response in Alzheimer's disease Models,” Neuron 114 (2026): P2741– 2758.e6, 10.1016/j.neuron.2026.03.011. PMC13051965 41928507 source

      The Results section on phagocytic activity (Figure 5C–E; page unavailable) reports significantly reduced Aβ uptake by microglia after Spi1/PU.1 deletion in APPPS1–21 mice, which were evaluated at 4 months of age (Results, Figure 2A). The phagocytosis assay used microglia isolated from harvested brains, not separate cortical and hippocampal measurements; those regional findings concern Aβ levels rather than phagocytosis. (LLM, conf=0.86)

      Experimental — accuracy not yet measured

  • The quote only partly states this claim.

    Premisecitation

    In PS19 (P301S) mice at 12 months of age, daily treatment with PU.1 inhibitor A11 for 6 weeks decreases phosphorylated tau in the hippocampus.

    “phosphorylated tau↓, learning and memory abilities↑”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [42] W. T. Ralvenius, A. E. Mungenast, H. Woolf, M. M. Huston, et al., “ A Novel Molecular Class That Recruits HDAC/MECP2 Complexes to PU.1 Motifs Reduces Neuroinflammation,” Journal of Experimental Medicine 220 (2023): 20222105, 10.1084/jem.20222105. PMC10465325 37642942 source

  • May combine two claims.

    Interpretationcitation

    In later stages of Alzheimer's disease, reducing PU.1 activity while increasing MEF2C activity inhibits harmful inflammation and supports neuroprotective microglial functions.

    “in the later stages, it might be beneficial to reduce PU.1 activity while increasing MEF2C activity to inhibit harmful inflammation and support neuroprotective microglial functions”
    Quote in the paperSubstantial claim4 of 4 sources checked
    • cites [22] K. L. Huang, E. Marcora, A. A. Pimenova, A. F. Di Narzo, et al., “ A Common Haplotype Lowers PU.1 Expression in Myeloid Cells and Delays Onset of Alzheimer's Disease,” Nature neuroscience 20 (2017): 1052– 1061. PMC5759334 28628103 source

      The Conditional and SMR analysis section (page not supplied) reports that lowering Spi1/PU.1 reduced inflammatory markers in mouse microglial cells and suggests it may blunt pro-inflammatory responses. It also raises a possible neuroprotective role, but does not establish a benefit specifically in later-stage Alzheimer’s disease or support increasing MEF2C activity; a search for MEF2C found no relevant passage. (LLM, conf=0.86)

      Experimental — accuracy not yet measured
    • cites [37] A. A. Pimenova, M. Herbinet, I. Gupta, S. I. Machlovi, et al., “ Alzheimer's‐associated PU.1 Expression Levels Regulate Microglial Inflammatory Response,” Neurobiology of Disease 148 (2021): 105217, 10.1016/j.nbd.2020.105217. PMC7808757 33301878 source

      The Discussion reports that PU.1 knock-down dampened inflammatory responses and suggests it may produce a neuroprotective microglial phenotype. But the paper proposes a possible benefit at disease onset, with later-stage clearance potentially preserved; it does not recommend increasing MEF2C activity or test the combined intervention in later-stage Alzheimer’s disease. MEF2C appears in the Introduction only as a factor that, together with PU.1, shapes microglial enhancers. (LLM, conf=0.88)

      Experimental — accuracy not yet measured
    • cites [42] W. T. Ralvenius, A. E. Mungenast, H. Woolf, M. M. Huston, et al., “ A Novel Molecular Class That Recruits HDAC/MECP2 Complexes to PU.1 Motifs Reduces Neuroinflammation,” Journal of Experimental Medicine 220 (2023): 20222105, 10.1084/jem.20222105. PMC10465325 37642942 source

      The Results section reports that reducing PU.1 activity decreased microgliosis and neurodegeneration in an AD-related mouse model, supporting the PU.1 part of the proposal. The paper does not establish that this approach is specifically beneficial in later-stage Alzheimer’s disease, and a search for MEF2C found no support for increasing its activity or for the proposed combined effect. (LLM, conf=0.88)

      Experimental — accuracy not yet measured
    • cites [46] F. Xue, J. Tian, C. Yu, H. Du, et al., “ Type I Interferon Response‐related Microglial Mef2c Deregulation at the Onset of Alzheimer's Pathology in 5×FAD Mice,” Neurobiology of Disease 152 (2021): 105272, 10.1016/j.nbd.2021.105272. PMC7956132 33540048 source

      The Discussion (page unavailable) associates reduced microglial MEF2C activation with inflammatory changes in 5×FAD mice, but explicitly says the study cannot establish a cause-and-effect relationship. The Results concern early AD pathology, not a later-stage intervention; the cited passages do not support reducing PU.1 activity or show that increasing MEF2C produces neuroprotective functions. (LLM, conf=0.84)

      Experimental — accuracy not yet measured

  • The quote only partly states this claim.

    Premisecitation

    In 5xFAD mice at 12 months of age, daily treatment with PU.1 inhibitor A11 for 6 weeks decreases Aβ plaque burden in the hippocampus.

    “Aβ plaque burden↓”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [42] W. T. Ralvenius, A. E. Mungenast, H. Woolf, M. M. Huston, et al., “ A Novel Molecular Class That Recruits HDAC/MECP2 Complexes to PU.1 Motifs Reduces Neuroinflammation,” Journal of Experimental Medicine 220 (2023): 20222105, 10.1084/jem.20222105. PMC10465325 37642942 source

  • The quote only partly states this claim.

    Premisecitation

    In PS19 (P301S) mice at 6 months of age, AAV-induced Mef2a/c overexpression increases cognition in the prefrontal cortex.

    “Mef2a/c overexpression = > cognition↑, hyperexcitability↓”
    Quote in the paperNot a substantial claim1 of 1 sources checked
    • cites [49] S. J. Barker, R. M. Raju, N. E. P. Milman, J. Wang, et al., “ MEF2 is a Key Regulator of Cognitive Potential and Confers Resilience to Neurodegeneration,” Science Translational Medicine 13 (2021): abd7695, 10.1126/scitranslmed.abd7695. PMC9258338 34731014 source

      In Results, Subhead 6, the paper reports that six-month-old PS19 (P301S) mice given an AAV construct to overexpress Mef2a/c showed faster fear-memory extinction than controls. This supports the cognitive improvement, but cognition was assessed by behavior, not measured specifically in the prefrontal cortex. The prefrontal-cortex recordings reported in the same section used a lentiviral construct to assess neuronal excitability. (LLM, conf=0.85)

      Experimental — accuracy not yet measured

  • May combine two claims.

    Premisecitation

    Microglial transcription factors regulate immune responses and maintain brain homeostasis.

    “Microglial transcription factors regulate immune responses and maintain brain homeostasis”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [13] H. Yeh and T. Ikezu, “ Transcriptional and Epigenetic Regulation of Microglia in Health and Disease,” Trends in Molecular Medicine 25 (2019): 96– 111, 10.1016/j.molmed.2018.11.004. PMC6377292 30578089 source

  • The quote only partly states this claim.

    Premisecitation

    In PS19 (P301S) mice at 6 months of age, AAV-induced Mef2a/c overexpression decreases hyperexcitability in the prefrontal cortex.

    “Mef2a/c overexpression = > cognition↑, hyperexcitability↓”
    Quote in the paperNot a substantial claim1 of 1 sources checked
    • cites [49] S. J. Barker, R. M. Raju, N. E. P. Milman, J. Wang, et al., “ MEF2 is a Key Regulator of Cognitive Potential and Confers Resilience to Neurodegeneration,” Science Translational Medicine 13 (2021): abd7695, 10.1126/scitranslmed.abd7695. PMC9258338 34731014 source

      The Results (Subhead 6; page not available) report reduced action-potential firing in PFC neurons of PS19 mice overexpressing Mef2a/c. However, those recordings used a lentiviral construct, not AAV. The stated age of 6 months applies to the fear-extinction experiment; the passage does not specify that age for the electrophysiology recordings. (LLM, conf=0.91)

      Experimental — accuracy not yet measured

  • Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

    Premisecitation

    Microglial development originates in primitive myeloid progenitors and depends on the transcription factors PU.1 and IRF8.

    “Microglial development originates in primitive myeloid progenitors and depends on the transcription factors PU.1 and interferon regulatory factor (IRF) 8 [29].”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [29] K. Kierdorf, D. Erny, T. Goldmann, V. Sander, et al., “ Microglia Emerge From Erythromyeloid Precursors via Pu.1‐ and Irf8‐dependent Pathways,” Nature neuroscience 16 (2013): 273– 280, 10.1038/nn.3318. 23334579 source

  • May combine two claims.

    Premisecitation

    IL-33 injection enhanced PU.1 transcriptional activity in an amyloid mouse model, resulting in increased Aβ clearance.

    “IL‐33 injection enhanced PU.1 transcriptional activity in an amyloid mouse model, resulting in increased Aβ clearance.”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [41] S.‐F. Lau, C. Chen, W.‐Y. Fu, J. Y. Qu, et al., “ IL‐33‐PU.1 Transcriptome Reprogramming Drives Functional State Transition and Clearance Activity of Microglia in Alzheimer's Disease,” Cell Reports 31 (2020): 107530, 10.1016/j.celrep.2020.107530. 32320664 source

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Premisecitation

    PU.1 and IRF8 cooperate to exert synergistic effects through a complex IRF-Erythroblast Transformation Specific (ETS) motif.

    “PU.1 and IRF8 cooperate to exert synergistic effects through a complex IRF‐Erythroblast Transformation Specific (ETS) motif.”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [29] K. Kierdorf, D. Erny, T. Goldmann, V. Sander, et al., “ Microglia Emerge From Erythromyeloid Precursors via Pu.1‐ and Irf8‐dependent Pathways,” Nature neuroscience 16 (2013): 273– 280, 10.1038/nn.3318. 23334579 source

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Premisecitation

    PU.1 serves as a core component of the HAF1 complex.

    “HAF1 and PU.1 are both functionally and physically connected, with PU.1 serving as a core component of the HAF1 complex [65].”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [65] K. S. Voo and D. G. Skalnik, “ Elf‐1 and PU.1 Induce Expression of gp91phox via a Promoter Element Mutated in a Subset of Chronic Granulomatous Disease Patients,” Blood 93 (1999): 3512– 3520, 10.1182/blood.V93.10.3512.410k19_3512_3520. 10233904 source

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Premisecitation

    The transcription factors BHLHE40/41 play roles in immune cell differentiation and function.

    “The transcription factors BHLHE40/41 play roles in immune cell differentiation and function.”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [51] R. Rauschmeier, C. Gustafsson, A. Reinhardt, and N. A‐Gonzalez, “ Bhlhe40 and Bhlhe41 Transcription Factors Regulate Alveolar Macrophage Self‐renewal and Identity,” The EMBO Journal 38 (2019): 101233, 10.15252/embj.2018101233. PMC6769426 31414712 source

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Premisecitation

    PU.1 occupancy at MEF2C regulatory regions has been reported.

    “Additionally, PU.1 occupancy at MEF2C regulatory regions has been reported [64], and MEF2C in turn regulates genes involved in synaptic support and anti‐inflammatory responses [45].”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [64] S. Stehling‐Sun, J. Dade, S. L. Nutt, R. P. DeKoter, et al., “ Regulation of Lymphoid versus Myeloid Fate 'choice' by the Transcription Factor Mef2c,” Nature Immunology 10 (2009): 289– 296, 10.1038/ni.1694. 19169261 source

  • May combine two claims.

    Interpretationreasoning

    Taken together, the microglial transcription factors PU.1, MEF2C, IRF8, and BHLHE40/41 are crucial in various immune system processes, regulating the expression of key pro-inflammatory mediators, cytokines, and innate immune receptors.

    “Taken together, the microglial transcription factors PU.1, MEF2C, IRF8, and BHLHE40/41 are crucial in various immune system processes, regulating the expression of key pro‐inflammatory mediators, cytokines, and innate immune receptors.”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Interpretationreasoning

    Dysregulation of microglial transcription factors significantly contributes to Alzheimer's disease pathogenesis by driving neuroinflammation, impairing clearance of Aβ and tau, and exacerbating neuronal damage.

    “Dysregulation of these factors significantly contributes to Alzheimer's disease pathogenesis by driving neuroinflammation, impairing the clearance of Aβ and tau, and exacerbating neuronal damage”
    Quote in the paperSubstantial claim
    • Rests on an assumption: Findings from mouse models of Alzheimer's disease are predictive of human Alzheimer's disease.

  • May combine two claims.

    Premisecitation

    In APP/PS1 (dE9) mice at 10-12 months of age, IL-33 treatment increases Aβ clearance and decreases amyloid burden in the cortex.

    “IL‐33 treatment = > Aβ clearance ↑ & Amyloid burden ↓, DB2313 abolished these phenotypes”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [41] S.‐F. Lau, C. Chen, W.‐Y. Fu, J. Y. Qu, et al., “ IL‐33‐PU.1 Transcriptome Reprogramming Drives Functional State Transition and Clearance Activity of Microglia in Alzheimer's Disease,” Cell Reports 31 (2020): 107530, 10.1016/j.celrep.2020.107530. 32320664 source
44 of 44

  • The paper relies on this without support.

    Microglial transcription factors have not yet progressed to human clinical trials.

    “However, despite their therapeutic potential, microglial transcription factors have not yet progressed to human clinical trials.”

  • The paper relies on this without support.

    Findings from mouse models of Alzheimer's disease are predictive of human Alzheimer's disease.

    “Current evidence suggests that microglial activation and functional changes, prominently observed in cortical and hippocampal regions during Alzheimer's disease pathology, may be ameliorated through transcriptional remodeling within microglia [35, 40, 41, 42, 48, 49].”
2 of 2

Cites

Flagged first, then by citations

Authors
Kim, B., Wang, S. S., Kim, J. R., & Kim, J.
Affiliations
  • Department of Medical & Molecular Genetics Indiana University School of Medicine Indianapolis Indiana USA
  • Indiana University Indianapolis (US)
ORCID
Venue
BioEssays
Publisher
Wiley
Published
2026-09-29
Volume
48
Issue
10
Pages
e70186-e70186
ISSN
  • 0265-9247 (ISSN-L)
  • 1521-1878
DOI
10.1002/bies.70186
PMC
PMC13623112
OpenAlex
W7214792411
Semantic Scholar
783aa18aaae22d91950cecd6cf67e042a681e9fc
Cited by
0
References
47
FWCI
0.00
Type
journal article
Language
en
Open access
Licence
Locations
  • BioEssays (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PubMed Central (submittedVersion, cc-by)
Funders
  • Alzheimer's Association (AARF‐21‐852175)
  • National Science Foundation (R01AG077829, R01AG071281, R21AG072738, RF1AG074543, P30AG072976)
Topics
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Multiple Sclerosis Research Studies
Keywords
Alzheimer's disease, microglia, transcriptional reprogramming, transcription factors, therapeutic target, PU.1, MEF2C, IRF8, myeloid cells, genetic susceptibility loci, gene expression networks, phagocytosis, neuroinflammation, neurotrophic support
MeSH terms
Interferon Regulatory Factor-8, Proto-Oncogene Protein Spi-1, Alzheimer Disease, Animals, Gene Expression Regulation, Humans, Transcription Factors, Transcription, Genetic, Trans-Activators, Microglia, Interferon Regulatory Factors, MEF2 Transcription Factors, Cellular Reprogramming

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Claims read by deepseek-v4.1-flash under definition version 3 (extract-v3) on 2026-10-17.

Classified by jev-1.13-20260917 (gold-guideline-v0.2) on 2026-10-17.

Cited sources are checked by gpt-6-sol.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review